STAT3 and lung cancer: Based on the findings above, we hypothesized that through restoring PDLIM2 expression to repress RelA and STAT3 activation, epigenetic drugs render lung cancer vulnerable to chemotherapeutic drugs and anti-PD-1 (Fig. 7a).